CDLX vs. API, TBRG, MIXT, MTLS, KLTR, ARQQ, BLZE, GCL, RXT, and HCAT
Should you be buying Cardlytics stock or one of its competitors? The main competitors of Cardlytics include Agora (API), TruBridge (TBRG), MiX Telematics (MIXT), Materialise (MTLS), Kaltura (KLTR), Arqit Quantum (ARQQ), Backblaze (BLZE), GCL Global (GCL), Rackspace Technology (RXT), and Health Catalyst (HCAT). These companies are all part of the "computer software" industry.
Cardlytics vs. Its Competitors
Cardlytics (NASDAQ:CDLX) and Agora (NASDAQ:API) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.
68.1% of Cardlytics shares are held by institutional investors. Comparatively, 40.4% of Agora shares are held by institutional investors. 4.4% of Cardlytics shares are held by company insiders. Comparatively, 14.6% of Agora shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Agora has a net margin of -33.74% compared to Cardlytics' net margin of -93.55%. Agora's return on equity of -7.70% beat Cardlytics' return on equity.
Agora has lower revenue, but higher earnings than Cardlytics. Agora is trading at a lower price-to-earnings ratio than Cardlytics, indicating that it is currently the more affordable of the two stocks.
Cardlytics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Agora has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
In the previous week, Cardlytics and Cardlytics both had 2 articles in the media. Cardlytics' average media sentiment score of 1.86 beat Agora's score of 1.44 indicating that Cardlytics is being referred to more favorably in the media.
Cardlytics received 210 more outperform votes than Agora when rated by MarketBeat users. Likewise, 56.68% of users gave Cardlytics an outperform vote while only 48.39% of users gave Agora an outperform vote.
Cardlytics presently has a consensus price target of $3.50, suggesting a potential upside of 104.68%. Agora has a consensus price target of $6.00, suggesting a potential upside of 50.75%. Given Cardlytics' higher possible upside, equities research analysts clearly believe Cardlytics is more favorable than Agora.
Summary
Cardlytics and Agora tied by winning 9 of the 18 factors compared between the two stocks.
Get Cardlytics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CDLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardlytics Competitors List
Related Companies and Tools
This page (NASDAQ:CDLX) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy CDLX Stock Free CDLX Stock Alerts